Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kaya HoldingsKAYS Equity-to-Asset is -2.75 as of Sep. 2025. The stock has 4 warning signs investors should review. Among 1,007 Drug Manufacturers companies, Kaya Holdings ranks worse than 97.32% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Kaya Holdings's Total Stockholders Equity for the quarter that ended in Sep. 2025 was $-0.55 Mil. Kaya Holdings's Total Assets for the quarter that ended in Sep. 2025 was $0.20 Mil.
Therefore, Kaya Holdings's Equity to Asset Ratio for the quarter that ended in Sep. 2025 was -2.75.
The historical rank and industry rank for Kaya Holdings's Equity-to-Asset or its related term are showing as below:
KAYS'
s Equity-to-Asset Range Over the Past 10 Years
Min: -84.56 Med: -10.7 Max: -2.75
Current: -2.75
During the past 12 years, the highest Equity to Asset Ratio of Kaya Holdings was -2.75. The lowest was -84.56. And the median was -10.70.
KAYS's Equity-to-Asset is ranked worse than 97.32% of 1007
companies
in the Drug Manufacturers industry
Industry Median: 0.6
vs KAYS: -2.75
Kaya Holdings (OTCPK:KAYS) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Kaya Holdings Equity-to-Asset Related Terms
Kaya Holdings Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Kaya Holdings's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
KAYS vs AYURF, CBSTQ, PNXP: Equity-to-Asset Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Kaya Holdings's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kaya Holdings Equity-to-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Kaya Holdings's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Kaya Holdings's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Kaya Holdings's Equity to Asset Ratio for the fiscal year that ended in Dec. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kaya Holdings (KAYS) has a Equity-to-Asset of -2.75 as of Sep. 2025. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Kaya Holdings and its competitors. According to the industry distribution chart, Kaya Holdings ranks #980 out of 1007 companies in the Drug Manufacturers industry, placing it in the top 97.3%.
Is Kaya Holdings' Equity-to-Asset too high?
Kaya Holdings' current Equity-to-Asset is -2.75. Based on the distribution chart, Kaya Holdings ranks #980 out of 1007 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does Kaya Holdings' Equity-to-Asset compare to AYURF and CBSTQ?
According to the Drug Manufacturers industry distribution chart, Kaya Holdings ranks #980 out of 1007 companies for Equity-to-Asset. This places Kaya Holdings in the lower half of its industry. The industry median Equity-to-Asset is 0.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Drug Manufacturers company?
The median Equity-to-Asset among Drug Manufacturers companies is 0.60, based on 1,007 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Kaya Holdings and its competitors. For the Drug Manufacturers industry, the median Equity-to-Asset is 0.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kaya Holdings's current Equity-to-Asset is -2.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kaya Holdings stock overvalued right now?
Kaya Holdings (KAYS) has a current Equity-to-Asset of -2.75. The current Equity-to-Asset is -2.75. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Kaya Holdings (KAYS), the current Equity-to-Asset is -2.75 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Kaya Holdings Inc is a holding company. It is focusing on wellness and mental health through operations in psychedelic treatment clinics, medical and recreational cannabis, and CBD products. The company own and operate a medical cannabis dispensary in the United States. Its has produced, distributed, and/or sold a full range of premium cannabis products including flower, oils, vape cartridges and cannabis infused confections, baked goods and beverages through a fully integrated group of subsidiaries and companies supporting distinctive brands.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KAYS has been successfully added to your 
